Proton Therapy and Bevacizumab for Primary Liver Tumors
Status:
Terminated
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
1. To evaluate the safety of the treatment of patients with technically or medically
inoperable hepatocellular carcinoma and cholangiocarcinoma with proton therapy and
concurrent bevacizumab biotherapy.
2. To identify the maximum tolerated dose (MTD) using this combination.
Secondary Objectives:
1. To evaluate local control rate within the radiation field, hepatic control rate outside
the treatment field, time to radiographic progression and 2 year survival rate.
2. To analyze dose-volume characteristics that influence the development of radiation
induced liver disease (RILD) and GI bleeds that may occur.
3. To assess quality of life during and after chemoradiation therapy.